Stevanato Group (STVN) AI Stock Analysis

• Market Cap: $4.02B
• Dividend Yield: 0.29%
• Average Volume (3M): 332.37K
• Price to Earnings (P/E): 25.9
• Beta (1Y): 0.71
• Revenue Growth: 9.19%
• EPS Growth: 23.06%
• Country: US
• Employees: 5,521
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Instruments & Supplies
• EPS (TTM): 0.21
• Shares Outstanding: 49,709,717
• 10 Day Avg. Volume: 278,451
• 30 Day Avg. Volume: 332,366
• PEG Ratio: -2.23
• Price to Book (P/B): 4.09
• Price to Sales (P/S): 5.20
• P/FCF Ratio: -36.39
• Enterprise Value/Market Cap: 0.95
• Enterprise Value/Revenue: 3.25
• Enterprise Value/Gross Profit: 11.36
• Enterprise Value/Ebitda: 13.62
• 1Y Price Target: $21.06
• Price Target Upside: 42.96% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 4
• EPS Forecast (FY): 0.63
• Revenue Forecast (FY): $1.28B

• Rating: 63 Neutral
• Price Target: $16.00 ▲(8.62% Upside)
• Action: Reiterated Date: 01/24/26
• Date: Action: Reiterated 01/24/26

The score is supported by a strong balance sheet and constructive earnings-call momentum (growth in high-value solutions and margin expansion with maintained guidance). It is held back by weak cash flow conversion and a bearish technical setup, with valuation also on the expensive side given the high P/E and low dividend yield.

Positive Factors

Strong balance sheet & capital structure

A low debt-to-equity ratio and a ~59.5% equity ratio provide durable financial flexibility to fund capacity expansion, absorb cyclical pharma demand swings, and support multi-year supply contracts. This reduces refinancing risk and preserves ability to invest in long-term growth initiatives.

High-value solutions mix driving growth

Nearly half of revenue now comes from rapidly growing, high-value consumables (Nexa syringes, EZ-fill vials). Such products are typically sticky, require regulatory qualification, and command higher margins, supporting more predictable recurring revenue and long-term margin resilience vs. one-off equipment sales.

Recent margin expansion and profitability

Material margin improvement reflects operational leverage and favorable product mix shift toward higher-margin drug containment solutions. Sustained margin expansion strengthens internal cash generation potential and funds reinvestment in capacity and R&D without immediate reliance on external capital.

Negative Factors

Weak free cash flow conversion

Severely depressed FCF conversion versus reported earnings limits the firm's ability to self-finance capex and working capital needs tied to capacity expansion. Persistently low FCF raises reliance on external funding, constrains discretionary returns, and reduces buffers against operational shocks.

Engineering segment underperformance

A double-digit decline and weak margins in Engineering point to structural execution or demand issues in capital-equipment projects. Slow order conversion and legacy project mix can produce volatile contribution swings, undermining diversification and creating ongoing margin pressure across reporting periods.

FX, tariff and supply-chain pressures

Meaningful currency and tariff headwinds create recurring revenue and margin variability across geographies. Combined with supply-chain and geopolitical risks noted in reports, these factors complicate long-term planning for capacity utilization and can erode contracted margins on multinational supply agreements.

Stevanato Group Business Overview & Revenue Model

Company Description

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for pharma and healthcare. Its principal products include containment solutions, drug delivery systems, medical devices, diagnostic, analytical services, visual inspection machines, assembling and packaging machines, and glass forming machines. The company was founded in 1949 and is headquartered in Piombino Dese, Italy. Stevanato Group S.p.A. operates as a subsidiary of Stevanato Holding S.R.L.

How the Company Makes Money

Stevanato Group generates revenue primarily through the sale of its glass packaging products and drug delivery systems to pharmaceutical and biotech companies. Key revenue streams include the manufacturing and sale of vials, syringes, and cartridges, which are critical for the storage and delivery of injectable drugs. Additionally, the company offers engineering services, including the design and implementation of automated systems for drug packaging and delivery, which further contributes to its earnings. Significant partnerships with major pharmaceutical companies enhance its revenue potential, as these collaborations often lead to long-term contracts and increased demand for its products. The company also benefits from a growing global demand for biologics and personalized medicine, which drives the need for innovative packaging solutions.

Stevanato Group Financial Statement Overview

Summary

Strong balance sheet (low debt-to-equity of 0.32 and high equity ratio of 59.54%) and healthy profitability (net margin 12.02%) support the score, but the sharp free cash flow deterioration (-110.26% TTM) and low free cash flow to net income (0.06) are notable risks.

Income Statement

Stevanato Group shows a steady revenue growth trajectory with a TTM revenue growth rate of 2.21%. The gross profit margin is stable at 28.63%, and the net profit margin is healthy at 12.02%. However, there is a slight decline in margins compared to previous years, indicating potential cost pressures or pricing challenges.

Balance Sheet

The company's balance sheet is strong with a low debt-to-equity ratio of 0.32, indicating prudent financial leverage. Return on equity is solid at 9.95%, reflecting efficient use of equity capital. The equity ratio stands at 59.54%, showcasing a robust capital structure.

Cash Flow

Cash flow analysis reveals challenges, with a significant decline in free cash flow growth at -110.26% TTM. The operating cash flow to net income ratio is moderate at 0.50, suggesting adequate cash generation relative to earnings. However, the free cash flow to net income ratio is low at 0.06, indicating limited free cash flow relative to profits.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.17B	1.10B	1.09B	983.68M	843.92M	662.04M
Gross Profit	335.13M	302.32M	339.89M	319.80M	265.40M	194.18M
EBITDA	279.53M	247.80M	272.35M	256.40M	226.93M	156.38M
Net Income	140.60M	117.78M	145.63M	142.85M	134.32M	78.51M
Balance Sheet
Total Assets	2.41B	2.33B	2.07B	1.66B	1.42B	967.98M
Cash, Cash Equivalents and Short-Term Investments	113.33M	98.27M	70.35M	256.65M	438.21M	157.12M
Total Debt	450.33M	428.97M	396.59M	218.37M	244.29M	363.01M
Total Liabilities	976.90M	924.43M	938.93M	663.79M	577.18M	657.84M
Stockholders Equity	1.44B	1.40B	1.13B	996.13M	842.07M	310.50M
Cash Flow
Free Cash Flow	-33.72M	-157.79M	-336.72M	-139.81M	20.16M	59.65M
Operating Cash Flow	235.60M	155.78M	105.21M	103.31M	133.34M	155.66M
Investing Cash Flow	-269.60M	-310.21M	-421.22M	-242.95M	-96.43M	-96.09M
Financing Cash Flow	-16.30M	183.22M	158.03M	-44.54M	254.85M	-26.52M

Stevanato Group Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 14.73
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For STVN, the sentiment is Negative. The current price of 14.73 is below the 20-day moving average (MA) of 15.51, below the 50-day MA of 17.97, and below the 200-day MA of 22.56, indicating a bearish trend. The MACD of -0.73 indicates Negative momentum. The RSI at 33.32 is Neutral, neither overbought nor oversold. The STOCH value of 26.74 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for STVN.

Stevanato Group Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
LMAT	78 Outperform	$2.46B	42.83	15.80%	0.95%	13.07%	27.98%
ATR	74 Outperform	$9.00B	23.76	15.28%	1.50%	2.50%	25.05%
MMSI	68 Neutral	$4.45B	35.21	8.67%	―	11.49%	-2.89%
STVN	63 Neutral	$4.02B	25.89	9.81%	0.29%	9.19%	23.06%
RGEN	60 Neutral	$6.93B	142.36	2.40%	―	11.74%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
TFX	50 Neutral	$5.40B	-16.61	-7.90%	1.11%	5.43%	-245.18%

Stevanato Group Corporate Events

Stevanato Group Exceeds Q3 Expectations and Advances Key Projects

On November 6, 2025, Stevanato Group held a conference call to discuss its third-quarter financial results, which exceeded expectations due to strong revenue growth and margin expansion. The company reported a 9% increase in revenue year-over-year, driven by a 14% growth in its BDS segment, primarily due to demand in its core drug containment business. Despite facing challenges from foreign currency and tariff costs, Stevanato remains on track to meet its 2025 guidance. The company is advancing its capital investment projects in Fishers and Latina to meet rising market demand, particularly in the biologics sector. Additionally, Stevanato’s commitment to sustainability was recognized with an EcoVadis Silver Medal, placing it in the top 15% of companies assessed globally.

The most recent analyst rating on (STVN) stock is a Hold with a $22.50 price target. To see the full list of analyst forecasts on Stevanato Group stock, see the STVN Stock Forecast page.

Stevanato Group Achieves 9% Revenue Growth in Q3 2025

Stevanato Group reported a 9% increase in revenue for the third quarter of 2025, reaching €303.2 million, with high-value solutions accounting for a record 49% of total revenue. The company’s Biopharmaceutical and Diagnostic Solutions segment drove this growth, offsetting a decline in the Engineering Segment. The financial results were bolstered by favorable product shipment timing and increased demand for high-performance Nexa® syringes. Despite challenges such as foreign currency impacts and tariff costs, Stevanato Group maintained its fiscal 2025 guidance, highlighting its strategic investments in capacity expansion and innovation to support future growth.

The most recent analyst rating on (STVN) stock is a Hold with a $26.00 price target. To see the full list of analyst forecasts on Stevanato Group stock, see the STVN Stock Forecast page.

Stevanato Group Discusses Q3 2025 Financial Results Amid Global Challenges

On November 6, 2025, Stevanato Group held an investor conference call to discuss its Q3 2025 financial results. The company is navigating various challenges, including global supply chain issues and geopolitical tensions, while focusing on expanding its capacity to meet customer demand. Despite these hurdles, Stevanato Group remains committed to optimizing its industrial footprint and enhancing its supply chain strategies, which are crucial for maintaining its competitive edge in the healthcare sector.

The most recent analyst rating on (STVN) stock is a Hold with a $26.00 price target. To see the full list of analyst forecasts on Stevanato Group stock, see the STVN Stock Forecast page.

Stevanato Group Releases Interim Financial Report for September 2025

Stevanato Group released its interim financial report for the three and nine months ending September 30, 2025, highlighting the company’s performance and strategic initiatives. The report provides insights into the company’s efforts to optimize its industrial footprint and enhance supply chain strategies amidst global economic challenges. The company faces risks related to market competition, supply chain disruptions, and geopolitical tensions, which could impact its operations and financial performance.

The most recent analyst rating on (STVN) stock is a Hold with a $26.00 price target. To see the full list of analyst forecasts on Stevanato Group stock, see the STVN Stock Forecast page.